KR960004315A - 약물학적 효능을 갖는 1-페닐-3-디메틸아미노프로판 화합물 - Google Patents

약물학적 효능을 갖는 1-페닐-3-디메틸아미노프로판 화합물 Download PDF

Info

Publication number
KR960004315A
KR960004315A KR1019950021738A KR19950021738A KR960004315A KR 960004315 A KR960004315 A KR 960004315A KR 1019950021738 A KR1019950021738 A KR 1019950021738A KR 19950021738 A KR19950021738 A KR 19950021738A KR 960004315 A KR960004315 A KR 960004315A
Authority
KR
South Korea
Prior art keywords
alkyl
meta
compound
phenyl
general formula
Prior art date
Application number
KR1019950021738A
Other languages
English (en)
Other versions
KR100364465B1 (ko
Inventor
부쉬만 헬무트
슈트라쓰부르거 볼프강
프리데리치스 엘마
Original Assignee
프란츠 비르츠, 파우쓰-베르그후스
그뤼넨탈 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6524045&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR960004315(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 프란츠 비르츠, 파우쓰-베르그후스, 그뤼넨탈 게엠베하 filed Critical 프란츠 비르츠, 파우쓰-베르그후스
Publication of KR960004315A publication Critical patent/KR960004315A/ko
Application granted granted Critical
Publication of KR100364465B1 publication Critical patent/KR100364465B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/62—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C07C217/72—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/20—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C219/22—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C07C225/08—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C07C225/10—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings with doubly-bound oxygen atoms bound to carbon atoms not being part of rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/58—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/33—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring
    • C07C323/35—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring the thio group being a sulfide group
    • C07C323/36—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring the thio group being a sulfide group the sulfur atom of the sulfide group being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Adhesive Tapes (AREA)

Abstract

본 발명은 1-페닐-3-디메틸아미노프로판 화합물, 이의 제조방법 및 약제학적 활성 성분으로서 이들 물질의 용도에 관한 것이다.

Description

약물학적 효능을 갖는 1-페닐-3-디메틸아미노프로판 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 생리학적으로 혼화성인 산의 염 또는 염기의 형태인 부분 입체이성체 또는 에난티오머로서의 일반식(Ⅰ)의 1-페닐-3-디메틸아미노프로판 화합물.
    상기 식에서, X는 OH,F,Cl,H 또는 OCOR6그룹(여기서, R6은 C1-3알킬이다)이고, R1은 C1-4-알킬 그룹을 나타내고, R3은 H 또는 직쇄 C1-4-알킬 그룹을 나타내거나 R2와 R3는 함께 C1-4사이클로알킬 라디칼을 형성하며, R5가 H일 경우, R4는 메타-O-Z(여기서, Z는 H, C1-3-알킬이다), PO(OC1-4-알킬)2, CO(C1-5-알킬), CONH-C6H4-(CC1-3-알킬) 또는 CO-C6H4-R7(여기서, R7은 오르토-OCOC1-3-알킬 또는 메타- 또는 파라-CH2N(R8)2이고, R8은 C1-4-알킬 또는 4-모르폴리노이다)이거나 R4가 메타-S-C1-3-알킬 또는 메타-Cl, 메타-F 또는 메타-CR9R10R11(여기서, R9R10및 R11은 H 또는 F이다), 오르토-OH, 오르토-O-C2-3-알킬 파라-F 또는 파라 CR9R10R11이거나, R5가 파라 위치에서 -Cl,-F,-OH 또는 -O-C1-3-알킬인 경우, R4는 메타-위치에서 -Cl,-F,-OH 또는 -O-C1-3-알킬이거나, R4와 R5는 함께 3,4-OCH=CH- 또는 3,4-OCH=CHO- 이다.
  2. 제1항에 있어서, X는 OH,F,Cl,H이고, R1은 C1-4-알킬 그룹이며, R2가 H 또는 CH3이고, R3가 H 또는 CH3이며, R5가 H일 경우 R4는 메타-OC1-3-알킬, 메타-OH, 메타-S-C1-3-알킬 또는 메타-F, 메타-Cl, 메타-CH3, 메타-CF2H, 메타-CF3또는 파라-CF3이거나, R5가 파라-Cl 또는 파라-F일 경우, R4가 메타-Cl 또는 메타-F이거나, R4와 R9가 함께 3,4-OCH=CH-인 일반식(Ⅰ)의 화합물.
  3. 제1항 또는 제2항에 있어서, 배열(Ia)의 부분입체이성체 형태로 존재하며 R2와 R3라디칼이 상이한 일반식(Ⅰ)의 화합물임을 특징으로 하는 화합물.
  4. 일반식(Ⅱ)의 β-디메틸아미노케톤을 일반식(Ⅲ)의 유기 금속 화합물과 반응시켜 X가 OH의 일반식(Ⅰ)의 화합물을 형성함을 특징으로 하여 제1항 내지 제3항중 어느 한 항에 따른 X가 OH의 일반식(Ⅰ)의 1-페닐-3-디메틸아미노프로판 화합물을 제조하는 방법.
    상기식에서, z는 MgCl,MgBr,MgI 또는 Li이다.
  5. X가 Cl인 일반식(Ⅰ)의 화합물을 아연 보로하이드라이드, 아연 시아노보로하이드라이드 및/또는 주석 시아노보로하이드라이드와 반응시킴을 특징으로 하여 제1항 내지 제3항중 어느 한 항에 따른 X가 H인 일반식(Ⅰ)의 1-페닐-3-디메틸아미노프로판 화합물을 제조하는 방법.
  6. X가 Cl인 일반식(Ⅰ)의 화합물을 용매에서 디메틸아미노설푸르 트리플루오라이드와 반응시킴을 특징으로 하여 제1항 내지 제3항중 어느 한 항에 따른 X가 F인 일반식(Ⅰ)의 1-페닐-3-디메틸아미노프로판 화합물을 제조하는 방법.
  7. X가 Cl인 일반식(Ⅰ)의 화합물을 티오닐 클로라이드와 반응시킴을 특징으로 하여 제1항 내지 제3항중 어느 한 항에 따른 X가 Cl인 일반식(Ⅰ)의 1-페닐-3-디메틸아미노프로판 화합물을 제조하는 방법.
  8. X가 Cl인 일반식(Ⅰ)의 화합물을 산 클로라이드 Cl-COOR6과 반응시킴을 특징으로 하여 제1항 내지 제3항중 어느 한 항에 따른 X가 OCOR6그룹(여기서, R6은 C1-3-알킬이다)인 일반식(Ⅰ)의 1-페닐-3-디메틸아미노프로판 화합물을 제조하는 방법.
  9. 약제학적 활성 성분으로서의 제1항 내지 제3항중 어느 한 항에 따른 일반식(Ⅰ)의 1-페닐-3-디메틸아미노프로판을 함유하는 진통제.
  10. 활성 성분으로서 제1항 내지 제3항중 어느 한 항에 따른 하나 이상의 일반식(Ⅰ)의 1-페닐-3-디메틸아미노프로판을 함유하는 진통제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950021738A 1994-07-23 1995-07-22 1-페닐-3-디메틸아미노프로판화합물,이의제조방법및이를포함하는진통제 KR100364465B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4426245.0 1994-07-23
DE4426245A DE4426245A1 (de) 1994-07-23 1994-07-23 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung

Publications (2)

Publication Number Publication Date
KR960004315A true KR960004315A (ko) 1996-02-23
KR100364465B1 KR100364465B1 (ko) 2003-02-05

Family

ID=6524045

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950021738A KR100364465B1 (ko) 1994-07-23 1995-07-22 1-페닐-3-디메틸아미노프로판화합물,이의제조방법및이를포함하는진통제

Country Status (31)

Country Link
US (3) US6248737B1 (ko)
EP (1) EP0693475B1 (ko)
JP (2) JP4034366B2 (ko)
KR (1) KR100364465B1 (ko)
CN (1) CN1077566C (ko)
AT (1) ATE163176T1 (ko)
AU (1) AU685644B2 (ko)
BR (1) BR9502390A (ko)
CA (1) CA2154424C (ko)
CO (1) CO4410179A1 (ko)
CZ (1) CZ286441B6 (ko)
DE (3) DE4426245A1 (ko)
DK (1) DK0693475T3 (ko)
ES (1) ES2115298T3 (ko)
FI (1) FI114704B (ko)
FR (1) FR12C0016I2 (ko)
GR (1) GR3026326T3 (ko)
HK (1) HK1005062A1 (ko)
HU (1) HU218481B (ko)
IL (1) IL113901A (ko)
LT (1) LTPA2011007I1 (ko)
LU (1) LU91793I2 (ko)
MY (1) MY114889A (ko)
NZ (1) NZ272623A (ko)
PE (1) PE34896A1 (ko)
PL (1) PL181169B1 (ko)
RU (1) RU2150465C1 (ko)
SI (1) SI0693475T1 (ko)
UA (1) UA41345C2 (ko)
UY (1) UY23992A1 (ko)
ZA (1) ZA956118B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210056548A (ko) * 2019-11-11 2021-05-20 한국생산기술연구원 탄탈륨-구리 합금의 제조방법 및 이로부터 제조된 탄탈륨-구리 합금

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0743853B1 (en) * 1994-02-08 2001-05-02 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
FR2745815B1 (fr) * 1996-03-08 1998-06-26 Synthelabo Derives de benzofurane, leur preparations et compositions pharmaceutiques les comprenant
EP0888324A1 (fr) * 1996-03-08 1999-01-07 Synthelabo Derives de 2-aminoethyl-benzofurane, leur preparation et leur application en therapeutique
DE19609847A1 (de) * 1996-03-13 1997-09-18 Gruenenthal Gmbh Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
DE19933421A1 (de) 1999-07-16 2001-01-25 Gruenenthal Gmbh 2-Benzyl-3-dimethylamino-1-phenyl-propanderi- vate
PE20010623A1 (es) * 1999-10-05 2001-07-07 Gruenenthal Chemie Uso de (+)-tramadol y/o o-demetiltramadol para tratamiento de urgencia urinaria incrementada y/o incontinencia urinaria
DE10000312A1 (de) * 2000-01-05 2001-07-12 Gruenenthal Gmbh Substituierte Aminomethyl-Phenyl-Cyclohexanderivate
DE10059412A1 (de) * 2000-11-30 2002-06-13 Gruenenthal Gmbh Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie der Harninkontinenz
DE10109763A1 (de) * 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
DE10146275A1 (de) 2001-09-18 2003-04-24 Gruenenthal Gmbh Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20080057011A1 (en) * 2001-12-12 2008-03-06 L'oreal S.A., Composition structured with a polymer containing a heteroatom and an Organogelator
DE10161809A1 (de) * 2001-12-14 2003-06-26 Gruenenthal Gmbh Arzneimittel enthaltend N,N'-disubstituierte Piperazin-Verbindungen
DE10161644A1 (de) * 2001-12-14 2003-06-26 Gruenenthal Gmbh N,N'-disubstituierte Piperazin-Verbindungen
DE10163421A1 (de) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
DE10224108A1 (de) * 2002-05-29 2004-01-29 Grünenthal GmbH 1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes Arzneimiitel mit verzögerter Wirkstofffreisetzung
US20050137194A1 (en) * 2002-05-29 2005-06-23 Gruenenthal Gmbh Combination of selected opioids with other active compounds for treatment of urinary incontinence
US7410965B2 (en) * 2002-05-29 2008-08-12 Gruenenthal Gmbh Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
DE10224624A1 (de) * 2002-05-30 2003-12-11 Gruenenthal Gmbh Metabolite und Prodrugs von 1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol
US20050137145A1 (en) * 2002-05-30 2005-06-23 Gruenenthal Gmbh Metabolites of 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol and their use in the treatment of urinary incontinence
DE10224556A1 (de) * 2002-05-31 2004-01-08 Grünenthal GmbH 1-Dimethylamino- 3-(3-methoxy-phenyl)2-methyl-pentan-3-ol entaltendes Arzneimittel in verschiedenen Formulierungen
DE10225315A1 (de) * 2002-06-06 2003-12-24 Gruenenthal Gmbh Wirkstoffsalze und Ester von 1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl- pentan-3-ol und 3-(3-Dimethylamino-1-ethyl-1-hydroxy-2-methyl- propyl)-phenol
US7550624B2 (en) * 2002-06-06 2009-06-23 Gruenenthal Gmbh Pharmaceutically active salts and esters of 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol and 3- (3-dimethylamino-1-ethyl-1-hydroxy-2-methylpropyl)-phenol and methods of using same
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10228192A1 (de) * 2002-06-24 2004-01-15 Grünenthal GmbH Darreichungsform zur oralen Verabreichung von Wirkstoffen, Vitaminen und/oder Nährstoffen
EP1558238A4 (en) * 2002-09-24 2006-08-30 Univ Virginia Commonwealth BETA-HYDROXYPHENYL ALDYLAMINE AND ITS USE FOR THE TREATMENT OF GLAUCOMA
HUE033042T2 (en) 2002-11-22 2017-11-28 Gruenenthal Gmbh Combination of selected analgesics with COX II inhibitors
DE10326097A1 (de) * 2003-06-06 2005-01-05 Grünenthal GmbH Verfahren zur Herstellung von Dimethyl-(3-aryl-butyl)-aminverbindungen
DE10328316A1 (de) 2003-06-23 2005-01-20 Grünenthal GmbH Verfahren zur Herstellung von Dimethyl-(3-aryl-buthyl)-aminverbindungen als pharmazeutische Wirkstoffe
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8075872B2 (en) * 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102004019916A1 (de) * 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
NZ551288A (en) * 2004-05-14 2010-10-29 Janssen Pharmaceutica Nv Carboxamido opioid compounds that are derivatives of tramadol
ATE368639T1 (de) * 2004-06-28 2007-08-15 Gruenenthal Gmbh Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
JP2008527035A (ja) * 2005-01-18 2008-07-24 ユニヴァーシテイ オブ フロリダ 疼痛を抑制するための組成物及び方法
US20060160905A1 (en) * 2005-01-18 2006-07-20 Bergeron Raymond J Jr Compositions and methods for inhibiting pain
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005033732B4 (de) * 2005-05-27 2014-02-13 Grünenthal GmbH Trennung stereoisomerer N,N-Dialkylamino-2-alkyl-3-hydroxy-3-phenyl-alkane
DE202005014347U1 (de) * 2005-09-09 2007-01-18 Grünenthal GmbH Applikationssystem für ein wirkstoffhaltiges Pflaster und Wirkstoffabgaberegulierungsmittel
US20090104266A1 (en) * 2005-09-15 2009-04-23 Tobias Jung 3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation
DE102005052588A1 (de) * 2005-11-02 2007-05-10 Grünenthal GmbH Verfahren zur Herstellung substituierter Dimethyl-(3-aryl-butyl)-amin-Verbindungen mittels homogener Katalyse
ES2356093T3 (es) * 2006-04-28 2011-04-04 Grünenthal GmbH Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y paracetamol.
US20070254960A1 (en) * 2006-04-28 2007-11-01 Gruenenthal Gmbh Pharmaceutical combination
PL2012763T3 (pl) * 2006-04-28 2011-08-31 Gruenenthal Gmbh Kombinacja farmaceutyczna zawierająca 3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenol i NSAID
PT2046726E (pt) * 2006-07-24 2010-04-15 Janssen Pharmaceutica Nv Preparação da (2r,3r)-3-(3-metoxifenil)-n,n,2- trimetilpentanamina
TWI401237B (zh) * 2006-07-24 2013-07-11 ３-〔（１ｒ，２ｒ）-３-（二甲基氨基）-１-乙基-２-甲基丙基〕酚之製備
TWI496762B (zh) 2006-07-24 2015-08-21 製備（１ｒ，２ｒ）-３-（３-二甲胺基-１-乙基-２-甲基-丙基）-酚之方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
DE102007019417A1 (de) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
US20090076164A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched tapentadol
EP3170494A3 (en) 2007-11-23 2017-09-06 Grünenthal GmbH Tapentadol compositions
HUE047275T2 (hu) * 2007-12-07 2020-04-28 Gruenenthal Gmbh (1R,2R)-3-(3-dimetil-amino-1-etil-2-metil-propil)-fenol kristályos módosításait tartalmazó gyógyszerek
NZ586792A (en) 2008-01-25 2012-09-28 Gruenenthal Chemie Tamper resistant controlled release pharmaceutical tablets form having convex and concave surfaces
RU2508092C2 (ru) 2008-05-09 2014-02-27 Грюненталь Гмбх Способ получения твердой лекарственной формы, в частности таблетки для фармацевтического применения, и способ получения прекурсора твердой лекарственной формы, в частности таблетки
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
TR201904388T4 (tr) 2008-09-05 2019-05-21 Gruenenthal Gmbh Pregabalin veya gabapentin ve 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolün farmasötik kombinasyonu.
SI2352494T1 (sl) 2008-10-30 2019-12-31 Gruenenthal Gmbh Nove in potentne dozirne oblike tapentadola
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
LT2424514T (lt) * 2009-04-30 2017-04-25 Grünenthal GmbH Tapentadolis reumatoidinio artrito skausmo gydymui
WO2011009604A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
CN102573805A (zh) 2009-07-22 2012-07-11 格吕伦塔尔有限公司 热熔挤出的控制释放剂型
CN102002065B (zh) * 2009-09-02 2014-09-10 上海特化医药科技有限公司 他喷他多的制备方法及其中间体
US8288592B2 (en) 2009-09-22 2012-10-16 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
IT1397189B1 (it) 2009-12-01 2013-01-04 Archimica Srl Nuovo processo per la preparazione di tapentadol e suoi intermedi.
WO2011080756A1 (en) * 2009-12-29 2011-07-07 Ind-Swift Laboratories Limited Process for the preparation of 1-phenyl-3-dimethylaminopropane derivatives
CN102711461A (zh) * 2009-12-29 2012-10-03 Mapi医药公司 用于制备他喷他多及相关化合物的中间体化合物和方法
WO2011092719A2 (en) * 2010-02-01 2011-08-04 Ind-Swift Laboratories Limited Process for the preparation of l-phenyl-3-dimethylaminopropane derivatives
WO2011095314A2 (en) 2010-02-03 2011-08-11 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
EP2542521A2 (en) 2010-03-05 2013-01-09 Actavis Group Ptc Ehf Improved resolution methods for isolating desired enantiomers of tapentadol intermediates and use thereof for the preparation of tapentadol
EP2556048A2 (en) 2010-04-05 2013-02-13 Actavis Group PTC EHF Novel process for preparing highly pure tapentadol or a pharmaceutically acceptable salt thereof
CA2832436C (en) 2010-04-07 2018-08-14 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
EP2383255A1 (en) 2010-04-28 2011-11-02 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
EP2566461A2 (de) 2010-05-05 2013-03-13 Ratiopharm GmbH Festes tapentadol in nicht-kristalliner form
ITMI20100924A1 (it) * 2010-05-21 2011-11-22 Fidia Farmaceutici Nuovo metodo di sintesi delle due forme enantiomeriche del tapentadol
EP2992877A1 (en) 2010-06-15 2016-03-09 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
EP2666765B1 (en) 2010-06-15 2017-01-04 Grünenthal GmbH Process for the preparation of substituted 3-(1-amino-2-methyl-pentane-3-yl)phenyl compounds
BR112012033644A2 (pt) 2010-06-30 2016-11-22 Gruenenthal Gmbh tapentadol para uso no tratamento de síndrome do intestino irritável
IT1401109B1 (it) 2010-07-02 2013-07-12 Archimica Srl Nuovo processo per la preparazione di tapentadol e suoi intermedi.
EP3653600A1 (en) * 2010-07-23 2020-05-20 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
WO2012023147A1 (en) 2010-08-16 2012-02-23 Indoco Remedies Limited Process for the preparation of tapentadol
PL2611426T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Postać dawkowania zawierająca nieorganiczne sole, odporna na zgniatanie
RU2607499C2 (ru) 2010-09-02 2017-01-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, которая содержит анионный полимер
CN101948397A (zh) * 2010-09-07 2011-01-19 天津泰普药品科技发展有限公司 镇痛药他喷他多重要中间体的制备方法
US8552219B2 (en) 2010-09-20 2013-10-08 Ind-Swift Laboratories Limited Process for preparing L-phenyl-3-dimethylaminopropane derivative
WO2012051246A1 (en) 2010-10-12 2012-04-19 Ratiopharm Gmbh Tapentadol hydrobromide and crystalline forms thereof
CZ302992B6 (cs) * 2010-12-30 2012-02-08 Zentiva, K.S. Zpusob výroby (2R,3R)-N,N-dimethyl-3-(3-hydroxyfenyl)-2-methylpentylaminu (tapentadolu)
CZ303115B6 (cs) * 2010-12-30 2012-04-11 Zentiva, K.S. Zpusob výroby (2R,3R)-N,N-dimethyl-3-(3-hydroxyfenyl)-2-methylpentylaminu
US20130296608A1 (en) 2011-01-27 2013-11-07 Symed Labs Limited Novel stereospecific synthesis of (-) (2s, 3s)-1-dimethylamino-3-(3-methoxyphenyl)-2-methyl pentan-3-ol
CN102617501A (zh) 2011-01-31 2012-08-01 中国科学院上海药物研究所 取代正戊酰胺类化合物、其制备方法及用途
EP3287123B1 (en) 2011-03-04 2020-04-22 Grünenthal GmbH Aqueous pharmaceutical formulation of tapentadol for oral administration
EP3025710A1 (en) 2011-03-04 2016-06-01 Grünenthal GmbH Parenteral administration of tapentadol
US9446008B2 (en) 2011-03-04 2016-09-20 Gruenenthal Gmbh Semisolid aqueous pharmaceutical composition containing tapentadol
DK2694049T3 (da) 2011-04-05 2019-01-02 Gruenenthal Gmbh Tapentadol til forebyggelse af kronificering af smerte
HUE047342T2 (hu) 2011-04-05 2020-04-28 Gruenenthal Gmbh Tapentadol a trigeminális neuralgiával kapcsolatos fájdalom kezelése során történõ alkalmazásra
CN102206164A (zh) * 2011-04-11 2011-10-05 中国药科大学 一种他喷他多中间体的制备方法
WO2012146978A2 (en) 2011-04-28 2012-11-01 Actavis Group Ptc Ehf A novel process for the preparation of tapentadol or a pharmaceutically acceptable salt thereof
EP2701693B1 (en) 2011-04-29 2017-08-23 Grünenthal GmbH Tapentadol for preventing and treating depression and anxiety
EP2530072A1 (en) 2011-06-03 2012-12-05 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
WO2013011477A1 (en) 2011-07-20 2013-01-24 Torrent Pharmaceuticals Ltd Pharmaceutical invention of tapentadol
US8853393B2 (en) 2011-07-29 2014-10-07 Anhui New Star Pharmaceutical Development Co., Ltd. Intermediate for preparing tapentadol or analogues thereof
JP6038138B2 (ja) * 2011-07-29 2016-12-07 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ３−［（１ｓ，２ｓ）−３−（ジメチルアミノ）−１−エチル−２−メチルプロピル］フェノールのくも膜下投与または硬膜外投与
PT2736497T (pt) 2011-07-29 2017-11-30 Gruenenthal Gmbh Comprimido resistente a adulteração proporcionando libertação imediata de fármaco
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
WO2013105109A1 (en) 2011-11-09 2013-07-18 Indoco Remedies Limited Process for the preparation of tapentadol
WO2013090161A1 (en) 2011-12-12 2013-06-20 Boehringer Ingelheim International Gmbh Stereoselective synthesis of tapentadol and its salts
CN102557851B (zh) * 2011-12-13 2014-03-26 安徽省新星药物开发有限责任公司 一种盐酸他喷他多及其类似物的合成方法
WO2013111161A2 (en) * 2012-01-10 2013-08-01 Msn Laboratories Limited Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof
WO2013120466A1 (en) 2012-02-17 2013-08-22 Zentiva, K.S. A new solid form of tapentadol and a method of its preparation
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
MX362357B (es) 2012-04-18 2019-01-14 Gruenenthal Gmbh Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis.
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP2674414A1 (en) 2012-06-15 2013-12-18 Siegfried AG Method for the preparation of 1-aryl-1-alkyl-3-dialkylaminopropane compounds
CN103159633B (zh) * 2012-07-06 2015-08-12 江苏恩华药业股份有限公司 他喷他多的制备方法及用于制备他喷他多的化合物
WO2014012653A1 (en) 2012-07-16 2014-01-23 Grünenthal GmbH Pharmaceutical patch for transdermal administration of tapentadol
CZ304576B6 (cs) * 2012-07-24 2014-07-16 Zentiva, K.S. Oxalát TAPENTADOLU a způsob jeho přípravy
BR112015009839A2 (pt) 2012-11-01 2017-07-11 Torrent Pharmaceuticals Ltd composição farmacêutica de tapentadol para administração parenteral
US9090539B2 (en) 2013-05-24 2015-07-28 Ampac Fine Chemicals Llc Compounds and methods for preparing substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
EP3003283A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
WO2015004245A1 (en) 2013-07-12 2015-01-15 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
EP3063125A4 (en) * 2013-11-01 2017-04-26 Sun Pharma Advanced Research Company Novel intermediate of tapentadol
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
WO2015075678A1 (en) 2013-11-21 2015-05-28 Unimark Remedies Ltd. A novel process for the preparation of 1-phenyl-3-aminopropane derivatives
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
SI3083551T1 (en) 2013-12-16 2018-04-30 Farma Grs, D.O.O. CRYSTAL FORM INTERMEDIATE TAPENTADOL
CN104803861B (zh) * 2014-01-27 2017-05-24 上海博邦医药科技有限公司 一种合成盐酸他喷他多的方法
CZ307492B6 (cs) 2014-02-04 2018-10-17 Zentiva, K.S. Pevná forma maleátu tapentadolu a způsob její přípravy
GB2523089A (en) * 2014-02-12 2015-08-19 Azad Pharmaceutical Ingredients Ag Stable polymorph form B of tapentadol hydrochloride
EP2942054A1 (en) 2014-05-09 2015-11-11 G.L. Pharma GmbH Slow-release pharmaceutical formulation
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
EP3166923B1 (en) 2014-07-10 2023-03-15 SpecGx LLC Process for preparing substituted phenylalkanes
WO2016156147A1 (en) 2015-03-27 2016-10-06 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
MX2017013637A (es) 2015-04-24 2018-03-08 Gruenenthal Gmbh Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes.
US10421050B2 (en) * 2015-05-22 2019-09-24 Digi-Star, Llc Utilization of a mobile agricultural weighing system to monitor and store ancillary operational data for diagnostic purposes on trailed and truck-mounted equipment
ES2869981T3 (es) 2015-05-26 2021-10-26 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composiciones para su uso en el tratamiento de la enfermedad de parkinson y trastornos relacionados
HUE058824T2 (hu) 2015-07-10 2022-09-28 SpecGx LLC Kétlépéses eljárás 3-szubsztituált fenilalkilaminok elõállítására
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
EP3377049B1 (en) 2015-11-17 2021-01-06 MSN Laboratories Private Limited Crystalline forms of tapentadol salts and process for preparation thereof
ES2966219T3 (es) 2016-04-19 2024-04-19 Ratiopharm Gmbh Fosfato de tapentadol amorfo
PE20190908A1 (es) 2016-09-23 2019-06-26 Gruenenthal Chemie Formulacion estable para la administracion parenteral de tapentadol
US10292948B2 (en) 2017-01-11 2019-05-21 Torrent Pharmaceuticals Limited Tapentadol nasal composition
RS65027B1 (sr) 2017-01-11 2024-01-31 Torrent Pharmaceuticals Ltd Nazalna kompozicija tapentadola
WO2019195775A1 (en) * 2018-04-06 2019-10-10 Flex Pharma, Inc. Tolperisone analogs and methods of use
US20210253513A1 (en) 2018-06-15 2021-08-19 Pharmathen S.A. A novel process for the preparation of tapentadol
GR1009751B (el) 2019-03-22 2020-05-29 "Φαρματεν Α.Β.Ε.Ε." Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει οξαλικη ταπενταδολη και μεθοδος παρασκευης αυτου
GR1009791B (el) 2019-03-26 2020-08-03 Φαρματεν Α.Β.Ε.Ε. Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει ταπενταδολη και μεθοδος παρασκευης αυτου
CN111056961A (zh) * 2019-11-13 2020-04-24 李晓强 3-((1s,2s)-3-二甲氨基-1-乙基-2-甲基丙基)苯酚盐酸盐的制备方法
WO2021175773A1 (en) 2020-03-02 2021-09-10 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
EP3875079A1 (en) 2020-03-02 2021-09-08 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
PL3875077T3 (pl) 2020-03-02 2024-03-11 Grünenthal GmbH Postać dawkowania zapewniająca przedłużone uwalnianie soli kwasu fosforowego tapentadolu
DE202020104285U1 (de) 2020-07-24 2020-12-18 Grünenthal GmbH Ethylcellulose-beschichtete Partikel enthaltend ein Salz aus Tapentadol und Phosphorsäure
DE202020005470U1 (de) 2020-11-10 2022-01-25 Grünenthal GmbH Darreichungsformen mit verlängerter Freisetzung eines Salzes von Tapentadol mit L-(+)-Weinsäure
HRP20221136T1 (hr) 2020-11-10 2022-11-25 Grünenthal GmbH Oblici za doziranje s produljenim otpuštanjem soli tapentadola s l-(+)-vinske kiseline
WO2022101247A1 (de) 2020-11-10 2022-05-19 Grünenthal GmbH Darreichungsformen mit verlängerter freisetzung eines salzes von tapentadol mit l-(+)-weinsäure
EP4011369A1 (en) 2020-12-14 2022-06-15 G.L. Pharma GmbH Aqueous pharmaceutical composition comprising tapentadol tartrate
EP4269384A1 (en) 2022-04-26 2023-11-01 KRKA, d.d., Novo mesto Method for crystallizing tapentadol intermediate, tapentadol intermediate of high purity, method of making tapentadol and tapentadol of high purity

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE124521C (ko)
US2662886A (en) 1949-01-28 1953-12-15 Winthrop Stearns Inc Substituted phenylpropylamines
DE1051281B (de) * 1955-07-05 1959-02-26 Bayer Ag Verfahren zur Herstellung von Derivaten der 1-Aryl-3-aminopropan-1-ole
US3328249A (en) 1965-06-21 1967-06-27 Sterling Drug Inc Process for counteracting depressive states
NL7403348A (ko) * 1973-03-19 1974-09-23
DD124521A1 (ko) 1976-03-16 1977-03-02
US4608391A (en) 1977-07-05 1986-08-26 Cornell Research Foundation Inc. Catecholamine derivatives, a process for their preparation and pharmaceutical compositions thereof
DE2732750A1 (de) * 1977-07-20 1979-02-08 Merck Patent Gmbh Basische thioaether und verfahren zu ihrer herstellung
US4404222A (en) 1980-08-25 1983-09-13 American Cyanamid Company Phenylethanolamine derivatives and acid addition salts thereof for enhancing the growth rate of meat-producing animals and improving the efficiency of feed utilization thereby
US4336269A (en) 1979-12-10 1982-06-22 Eli Lilly And Company Para-nitrophenylalkylamines
DE3242922A1 (de) 1982-11-20 1984-05-24 Basf Ag, 6700 Ludwigshafen Phenylpropanolamine, ihre herstellung und verwendung
IT1213219B (it) 1984-09-28 1989-12-14 Consiglio Nazionale Ricerche Derivati amminoalchilnaftalenici ad attivita' farmacologica.
US4843160A (en) 1984-10-01 1989-06-27 The Dow Chemical Company Preparation of alpha-aminoalkylphenols
US5059422A (en) 1985-07-29 1991-10-22 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
US5169633A (en) 1985-07-29 1992-12-08 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
US4857553A (en) 1987-08-06 1989-08-15 A. H. Robins Company, Incorporated Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
SE8800207D0 (sv) * 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5135955A (en) 1988-04-25 1992-08-04 Eli Lilly And Company Propanamine derivatives
AU623676B2 (en) 1988-08-24 1992-05-21 Mochida Pharmaceutical Co., Ltd. Hydantoin derivatives
DK258389D0 (da) * 1989-05-26 1989-05-26 Ferrosan As Aryloxyphenylpropylaminer, deres fremstilling og anvendelse
EP0507863A4 (en) 1989-12-28 1993-07-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
ZA916555B (en) 1990-08-27 1993-04-28 Lilly Co Eli Method of treating inflammatory bowel disease
US5281623A (en) 1990-08-27 1994-01-25 Eli Lilly And Company Method for treating inflammation
US5280046A (en) 1991-02-22 1994-01-18 The University Of Colorado Foundation, Inc. Method of treating type I diabetes
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5419993A (en) 1991-11-01 1995-05-30 Canon Kabushiki Kaisha Polyamide, electrophotographic photosensitive member employing the polyamide, and electrophotographic apparatus, device unit and facsimile machine employing the member
US6071970A (en) * 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6017965A (en) * 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US5322859A (en) 1993-02-08 1994-06-21 University Of Iowa Research Foundation Antiglaucoma drug composition and method
US5387614A (en) 1993-07-27 1995-02-07 University Of Iowa Research Foundation Use of sigma receptor ligands as salivary gland stimulants
EP0743853B1 (en) * 1994-02-08 2001-05-02 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
DK0762877T3 (da) 1994-06-03 2001-07-16 Thejmde Trust Meta-substituerede arylalkylaminer og terapeutiske og diagnostiske anvendelser deraf
PL183499B1 (pl) 1994-10-21 2002-06-28 Nps Pharma Inc Związki do modulowania receptorów wapniowych i kompozycje farmaceutyczne
DE19525137C2 (de) 1995-07-11 2003-02-27 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe
US5648541A (en) 1995-09-28 1997-07-15 Nps Pharmaceuticals, Inc. Chiral reductions of imines leading to the syntheses of optically active amines
US5830509A (en) 1996-02-07 1998-11-03 West; Daniel David Microparticle complexes with 2-amino-1-phenylpropanol materials
DE19609847A1 (de) * 1996-03-13 1997-09-18 Gruenenthal Gmbh Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe
DE69733649T2 (de) * 1996-04-09 2006-05-18 NPS Pharmaceuticals, Inc., Salt Lake City Calcylitische verbindungen
US5981599A (en) * 1996-05-01 1999-11-09 Nps Pharmaceuticals, Inc. Inorganic ion receptor active compounds
US6052610A (en) * 1998-01-09 2000-04-18 International Business Machines Corporation Magnetic catheter tracker and method therefor
US6011066A (en) 1998-02-02 2000-01-04 Veterans General Hospital-Taipei Method for treating septic shock
DE19915601A1 (de) 1999-04-07 2000-10-19 Gruenenthal Gmbh 3-Amino-3-arylpropan-1-ol-Derivate, deren Herstellung und Verwendung
TWI291871B (en) 2000-11-01 2008-01-01 Cognition Pharmaceuticals Llc Pharmaceutical compositions and use of amphetamine compounds for improving memory and learning

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210056548A (ko) * 2019-11-11 2021-05-20 한국생산기술연구원 탄탈륨-구리 합금의 제조방법 및 이로부터 제조된 탄탈륨-구리 합금

Also Published As

Publication number Publication date
FR12C0016I2 (fr) 2013-01-11
FI953523A (fi) 1996-01-24
JP4034366B2 (ja) 2008-01-16
CA2154424A1 (en) 1996-01-24
DE4426245A1 (de) 1996-02-22
DE122011000007I1 (de) 2011-06-16
AU2713895A (en) 1996-02-08
RU95113154A (ru) 1997-06-27
JPH0899939A (ja) 1996-04-16
USRE39593E1 (en) 2007-04-24
UY23992A1 (es) 1995-08-02
FI953523A0 (fi) 1995-07-21
EP0693475B1 (de) 1998-02-11
JP2007084574A (ja) 2007-04-05
CZ190495A3 (en) 1996-05-15
CZ286441B6 (en) 2000-04-12
JP4846552B2 (ja) 2011-12-28
MY114889A (en) 2003-02-28
CN1077566C (zh) 2002-01-09
SI0693475T1 (en) 1998-06-30
HUT74100A (en) 1996-11-28
ATE163176T1 (de) 1998-02-15
US20020010178A1 (en) 2002-01-24
KR100364465B1 (ko) 2003-02-05
CN1125221A (zh) 1996-06-26
IL113901A (en) 1999-05-09
FR12C0016I1 (ko) 2012-04-06
PL309734A1 (en) 1996-02-05
PL181169B1 (pl) 2001-06-29
DK0693475T3 (da) 1998-09-23
CA2154424C (en) 2008-04-15
EP0693475A1 (de) 1996-01-24
ZA956118B (en) 1996-05-31
HU9502146D0 (en) 1995-09-28
CO4410179A1 (es) 1997-01-09
HK1005062A1 (en) 1998-12-18
PE34896A1 (es) 1996-09-07
GR3026326T3 (en) 1998-06-30
LU91793I2 (fr) 2011-05-02
HU218481B (hu) 2000-09-28
DE59501431D1 (de) 1998-03-19
UA41345C2 (uk) 2001-09-17
IL113901A0 (en) 1995-08-31
US6248737B1 (en) 2001-06-19
AU685644B2 (en) 1998-01-22
FI114704B (fi) 2004-12-15
US6344558B1 (en) 2002-02-05
NZ272623A (en) 1996-02-27
LTPA2011007I1 (lt) 2018-08-10
RU2150465C1 (ru) 2000-06-10
BR9502390A (pt) 1996-02-27
ES2115298T3 (es) 1998-06-16

Similar Documents

Publication Publication Date Title
KR960004315A (ko) 약물학적 효능을 갖는 1-페닐-3-디메틸아미노프로판 화합물
KR880012526A (ko) l-페닐-3-나프탈레닐옥시프로판아민
KR920005840A (ko) 이소티아졸 카르복실산 유도체, 이것을 유효성분으로한 벼 도열병 방지제, 및 상기 방제제를 사용한 벼 도열병 방제방법
EP0926132A3 (en) Fatty amine derivatives of butylated hydroxy toluene for the protection of surfaces from physical and chemical degradation
MX9206313A (es) Composicion de aditivos, baños acidos de plaqueado de zinc y aleaciones de zinc y metodos para el electrodeposito de zinc y aleaciones de zinc
ES8503666A1 (es) Procedimiento para la preparacion de 1-ariloxi-2,3,4,5-tetrahidro-3-benzazepinas
KR920006358A (ko) 1-메틸카르바펜엠 유도체 및 그의 제조방법
KR840001555A (ko) 치환된 2-페닐-2-(피리딜욕시)-에틸아민과 그의 등 배전자화합물 및 그들의 산부가염을 제조하는 방법
US4810262A (en) Fuel compositions
EP0504404A4 (en) Process for producing 3-substituted thio-3-cephem compound
KR860003212A (ko) 2-피리딘-티올 유도체 및 그의 산부가염의 제조 방법
CA2038029A1 (en) 1-alkyl-, 1-alkenyl- and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds, a process and intermediates for their preparation and theeir use as medicaments
KR900014407A (ko) 퀴놀린 카르복실산 유도체 및 이를 함유하는 항균제
KR860001815A (ko) 옥타하이드로-옥사졸로[4,5-g]퀴놀린의 제조방법
KR940000454A (ko) 신규 아졸 유도체, 그의 제조 방법 및 이 유도체를 함유하는 항진균제 및 항아로마타아제제
KR840004055A (ko) 진통 및 소염의 효능을 갖는 화합믈의 제조방법
KR880002826A (ko) 치환된 하이드록시프로필아민 유도체
KR930700410A (ko) 새로운 질소함유 화합물과 그 제조방법 및 용도
JPS6047271B2 (ja) 新規なシクロプロピルメチルアミン誘導体及びその製造法
KR900014334A (ko) 신규 화합물
KR870011144A (ko) 세팔로스포린 유도체의 제조방법
KR840000513A (ko) 1,5-벤조티아제핀 유도체의 제조법법
KR910000753A (ko) 신규한 세펨 유도체
CA2363543A1 (en) Fatty amine derivatives of butylated hydroxy toluene for the protection of surfaces from physical and chemical degradation
KR950017962A (ko) 퀴놀론 유도체의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121031

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20131101

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20141107

Year of fee payment: 13

A101 Application to extend term of patent right by permit